ライフサイエンスコーパス: glycosylated hemoglobin

1 inhibitors [AGIs], and insulin adjusted for glycosylated hemoglobin).

2 001) between serum protein argpyrimidine and glycosylated hemoglobin.

3 values, as well as significant decreases in glycosylated hemoglobin.

4 tis is associated with a slight elevation in glycosylated hemoglobin.

5 cerides, SBP, DBP, BMI, waist/hip ratio, and glycosylated hemoglobin.

6 esterol, total to HDL cholesterol ratio, and glycosylated hemoglobin].

7 lic blood pressure (-9.37 mm Hg; p < 0.001), glycosylated hemoglobin (-0.92%; p < 0.001), and smoking

8 table plaque and healed infarct had elevated glycosylated hemoglobin (10.2 +/- 5.0% versus 6.4 +/- 0.

9 n, mean diabetes duration 29 years, and mean glycosylated hemoglobin 7.9%).

10 f fasting serum glucose, insulin, C-peptide, glycosylated hemoglobin A (HbA1c), and Homeostasis Model

11 The percentage of glycosylated hemoglobin A1c (%GHbA1c) in human whole blo

12 with fluorinated compounds to detect tHb and glycosylated hemoglobin A1c (GHbA1c) in human whole bloo

13 ation of less than 7.8 mmol/L (140 mg/dL) or glycosylated hemoglobin A1c (HbA1c) below 7% is unknown.

14 Research targeting glycosylated hemoglobin A1c (HbA1c) to <6.5% to prevent

15 Elevated levels of glycosylated hemoglobin A1c (OR, 1.47; 95% CI, 1.26-1.71

16 plasma glucose by 0.69 mmol/L [1.32; 0.07], glycosylated hemoglobin A1C by 0.37% [0.54; 0.20], body

17 gender, body mass index, diabetes duration, glycosylated hemoglobin A1c, and fasting C-peptide.

18 tegerin, osteocalcin, osteopontin, and serum glycosylated hemoglobin A1c, insulin, and glucose were a

19 adjusting for duration of diabetes mellitus, glycosylated hemoglobin A1c, statin use, and end-stage r

20 assessment-estimated insulin resistance, and glycosylated hemoglobin A1c.

21 herapy during the DCCT, smoking, and greater glycosylated hemoglobin and AER at DCCT closeout but not

22 tively and significantly related to maternal glycosylated hemoglobin and plasma glucose.

23 yperglycemic at 26 weeks of age had elevated glycosylated hemoglobin and sciatic nerve sorbitol level

24 six subjects with normal fasting glucose and glycosylated hemoglobin and seven overtly diabetic subje

25 and duration of diabetes, level of control (glycosylated hemoglobin), and demographic data were reco

26 f diabetes, treatment group, smoking status, glycosylated hemoglobin, and AER.

27 justment for age, sex, duration of diabetes, glycosylated hemoglobin, and blood pressure.

28 Weights, blood sugar, glycosylated hemoglobin, and detailed ERGs were recorded

29 Serum lipids and lipoproteins, glycosylated hemoglobin, and the urinary albumin excreti

30 s in a 24-site US AMI registry (2005-08) had glycosylated hemoglobin assessed at a core laboratory, w

31 terol, high-density lipoprotein cholesterol, glycosylated hemoglobin, cigarette smoking) in addition

32 Total cholesterol (TC), HDL cholesterol, glycosylated hemoglobin, cigarette smoking, and hyperten

33 Fasting plasma glucose and glycosylated hemoglobin concentrations returned to norma

34 Blood-glycosylated hemoglobin concentrations were not signific

35 ithout affecting body weight, blood glucose, glycosylated hemoglobin, creatinine, or creatinine clear

36 The mean levels of glycosylated hemoglobin decreased by 1.0% in the 4 mg/d

37 adjusting for age, gender, body mass index, glycosylated hemoglobin, diabetes duration, systolic blo

38 r decline was higher after age 35 yr or when glycosylated hemoglobin exceeded 9% but did not vary wit

39 low-up, subjects who were in "poor" control (glycosylated hemoglobin (GHb) > or = 11%) at baseline we

40 han values in the WT mice; blood glucose and glycosylated hemoglobin (GHb) levels did not differ in t

41 nsive description of glycemic control (total glycosylated hemoglobin (GHb)) up to 4.5 years duration

42 cholesterol, multivessel CAD, diabetes with glycosylated hemoglobin >7%, and persistent angina were

43 e the variables baseline body mass index and glycosylated hemoglobin have missing values.

44 on quality was significantly associated with glycosylated hemoglobin (Hb A(1c)) levels.

45 strates that hydroxychloroquine (HCQ) lowers glycosylated hemoglobin (HbA(1c) ) in diabetes patients

46 primary outcome (simultaneous control with a glycosylated hemoglobin (HbA(1c)) <7.0%, blood pressure

47 y disease; however, the relationship between glycosylated hemoglobin (HbA(1c)) as a marker of chronic

48 aptoglobin (Hp) polymorphism rs#72294371 and glycosylated hemoglobin (HbA(1c)) on risk of coronary he

49 al glucose tolerance test); 2) with baseline glycosylated hemoglobin (HbA1) less than 9%; and 3) who

50 8 (16.8) U/d of insulin, and had a mean (SD) glycosylated hemoglobin (HbA1) level of 10.0% (1.9%).

51 current smokers (grade A), and patients with glycosylated hemoglobin (HbA1C) >/= 6.5% (grade B).

52 current smokers (grade A), and patients with glycosylated hemoglobin (HbA1C) >/= 6.5% (grade B).

53 ncluded low-density lipoprotein </= 70mg/dl, glycosylated hemoglobin (HbA1c) </= 6.5%, and systolic b

54 4, OR10-14 years = 2.07, OR15+years = 3.99), glycosylated hemoglobin (HbA1c) (OR6.5-6.9% = 1.33, OR7-

55 designed to examine the relationship between glycosylated hemoglobin (HbA1C) and adverse outcomes in

56 abetes control was assessed by percentage of glycosylated hemoglobin (HbA1c) and divided into three c

57 the effects of ranolazine versus placebo on glycosylated hemoglobin (HbA1c) at 6- and 12-month follo

58 The duration of DM and the glycosylated hemoglobin (HbA1c) levels of the patients i

59 diators did not correlate with age, race, or glycosylated hemoglobin (HbA1C) levels.

60 risk of those outcomes at both high and low glycosylated hemoglobin (HbA1c) levels.

61 nother agent in the 120 days after the index glycosylated hemoglobin (HbA1C) measurement.

62 Mental State Examination of 28.6 +/- 1.5, a glycosylated hemoglobin (HbA1C) of 5.88 +/- 0.74%, and a

63 Recently, glycosylated hemoglobin (HbA1c) of 6.5% or higher (>/= 4

64 Glycosylated hemoglobin (HbA1c) was assessed using a cha

65 the levels of the fasting plasma glucose and glycosylated hemoglobin (HbA1c) were compared in both gr

66 Body mass index, glycosylated hemoglobin (HbA1c), and DPN [quantified by

67 nder-the-curve glucose after glucose load or glycosylated hemoglobin (HbA1c), and measures of insulin

68 index (BMI), blood pressure, serum glucose, glycosylated hemoglobin (HbA1c), blood urea nitrogen, se

69 Admission glycosylated hemoglobin (HbA1c), glucose levels, and com

70 rement of random blood glucose levels, serum glycosylated hemoglobin (HbA1c), serum porcine C peptide

71 short-term reduction in the concentration of glycosylated hemoglobin (HbA1c).

72 association between H. pylori and levels of glycosylated hemoglobin (HbA1c).

73 h type 2 diabetes and poor glycemic control (glycosylated hemoglobin [HbA1c] levels > or =8.0%) and p

74 DM (mean duration, 7.7 [SD, 7.2] years; mean glycosylated hemoglobin [HbA1c] value, 7.4% [SD, 1.0%]),

75 hypertension (>130/80 mm Hg) and type 2 DM (glycosylated hemoglobin [HbA1c], 6.5%-8.5%) and were rec

76 factor changes (fasting blood glucose [FBG], glycosylated hemoglobin [HbA1c], systolic or diastolic b

77 s to these bacteria, and blood sugar levels (glycosylated hemoglobin, HbAlc) were studied before and

78 estimates for glycosylated hemoglobin (total glycosylated hemoglobin, hemoglobin A1, or hemoglobin A1

79 r increased extent of macular edema), higher glycosylated hemoglobin, history of diabetic neuropathy,

80 sting glucose is 91.6+/-13.8 mg/dl, and mean glycosylated hemoglobin is 5.1+/-0.7% (normal range: 4.3

81 Glycosylated hemoglobin is an indicator of long-term gly

82 he purpose of this study was to determine if glycosylated hemoglobin is elevated in patients with per

83 luded age, gender, BP, body mass index, GFR, glycosylated hemoglobin, LDL cholesterol, HDL cholestero

84 inuria of short duration, salutary levels of glycosylated hemoglobin (less than 8 percent), low systo

85 represented a 1-percentage point increase in glycosylated hemoglobin level (95% CI, 1.10 to 1.26) in

86 ssure (diabetic and nondiabetic patients) or glycosylated hemoglobin level (diabetic patients only).

87 hospitalization were longitudinally measured glycosylated hemoglobin level (rate ratio = 1.5 per 2% i

88 among patients with diabetes, only 28% had a glycosylated hemoglobin level measured.

89 of metformin-rosiglitazone, 28.1% achieved a glycosylated hemoglobin level of 7% or less [corrected].

90 ose level of 12.0 mmol/L (216 mg/dL), a mean glycosylated hemoglobin level of 8.8%, and a mean body m

91 during the open treatment phase (mean +/- SD glycosylated hemoglobin level reduction, -0.4% +/- 1.4%;

92 diabetes, chronic hyperglycemia (assessed by glycosylated hemoglobin level) is related to the develop

93 waist-to-hip ratio, physical activity index, glycosylated hemoglobin level, and other factors.

94 italization in the preceding 6 months, lower glycosylated hemoglobin level, and questionnaire respons

95 controlling for age, sex, cigarette smoking, glycosylated hemoglobin level, insulin use, plasma C-pep

96 gnificantly correlated with blood glucose or glycosylated hemoglobin level.

97 sting glucose: 9.9 (2.5) mmol/dL, and HbA1c (glycosylated hemoglobin) level: 8.9% (1.2%).

98 Glycosylated hemoglobin levels and insulin doses were al

99 style, there was a significant difference in glycosylated hemoglobin levels between those who rated t

100 Glycosylated hemoglobin levels decreased during the open

101 Deaths and mean glycosylated hemoglobin levels did not differ between th

102 reatment are associated with improvements in glycosylated hemoglobin levels for at least 1 year.

103 ble to discontinue insulin therapy and their glycosylated hemoglobin levels improved.

104 Glycosylated hemoglobin levels remained significantly lo

105 Mean glycosylated hemoglobin levels were 5.2+/-0.9% (off ster

106 our postdextrose glucose concentrations, and glycosylated hemoglobin levels were available from 11 27

107 than for white girls in every age group, and glycosylated hemoglobin levels were highest for black an

108 reports from 1966 through June 1994 in which glycosylated hemoglobin levels were measured concurrentl

109 Post-treatment glycosylated hemoglobin levels were not different in the

110 ferent in the two groups, but follow-up mean glycosylated hemoglobin levels were significantly better

111 Glycosylated hemoglobin levels, fasting plasma glucose l

112 ts, emergency department visits, death rate, glycosylated hemoglobin levels, medications, and past me

113 tory; glycemic control was measured by using glycosylated hemoglobin levels.

114 mproved glucose tolerance and a reduction in glycosylated hemoglobin levels.

115 iabetic medication were further adjusted for glycosylated hemoglobin levels.

116 ch was assessed via serial determinations of glycosylated hemoglobin levels.

117 also associated in the CVRF-free group with glycosylated hemoglobin levels.

118 ssure, high-density lipoprotein cholesterol, glycosylated hemoglobin, lipoprotein(a) and fibrinogen l

119 e <120/80 mm Hg, fasting glucose <100 mg/dl, glycosylated hemoglobin <5.7%, and total cholesterol <20

120 [systolic <130 mm Hg; diastolic <80 mm Hg], glycosylated hemoglobin <7%) in BARI 2D.

121 or pneumococcal vaccination to 88% for serum glycosylated hemoglobin measurement.

122 t, blood pressure, random serum glucose, and glycosylated hemoglobin measurements.

123 of diabetic retinopathy was associated with glycosylated hemoglobin (odds ratio [OR], 1.27; 95% CI,

124 sly unknown DM, defined by a core laboratory glycosylated hemoglobin of >/=6.5%.

125 nor documentation of DM in the chart (median glycosylated hemoglobin of unrecognized patients, 6.7%;

126 to the previously established role for total glycosylated hemoglobin, other factors including height,

127 plasma glucose concentration, percentage of glycosylated hemoglobin, plasma insulin concentration, a

128 rs of progression to definite DSP were total glycosylated hemoglobin (relative risk (RR) for increase

129 Glycosylated hemoglobin, serum glucose while fasting, se

130 and endorsed as an acceptable screen for DM, glycosylated hemoglobin testing should be considered for

131 Glucose tolerance, C-peptide, and glycosylated hemoglobin tests confirmed the restoration

132 Moreover, by measuring total glycosylated hemoglobin (TGH) in 997 pregnant women as a

133 rovascular disease; however, the relation of glycosylated hemoglobin to macrovascular disease is less

134 MI); lipid profile; and levels of glucose or glycosylated hemoglobin, to identify those with metaboli

135 Adjusted relative risk estimates for glycosylated hemoglobin (total glycosylated hemoglobin,

136 e incidence of neuropathy was related to the glycosylated hemoglobin value and the duration of diabet

137 liter], P<0.001), respectively, and the mean glycosylated hemoglobin value decreased 1.2 percentage p

138 ent glycosylated hemoglobin value, change in glycosylated hemoglobin value during the follow-up perio

139 ary albumin excretion rate and with the mean glycosylated hemoglobin value during the mean duration (

140 The absolute decrease in the glycosylated hemoglobin value was 1.9 percent (95 percen

141 we found that duration of diabetes, current glycosylated hemoglobin value, change in glycosylated he

142 Poorly controlled diabetes was defined as glycosylated hemoglobin values > 8%.

143 Minimal differences in mean glycosylated hemoglobin values (HbAlc) were noticed befo

144 The adjusted mean glycosylated hemoglobin values decreased by 0.8 and 1.4

145 The mean glycosylated hemoglobin values have been dramatically re

146 ations during fasting and postprandially and glycosylated hemoglobin values were measured periodicall

147 nsulin-dependent (type 2) diabetes mellitus (glycosylated hemoglobin values, 8 to 12 percent; normal,

148 Glycosylated hemoglobin was only measured in patients wi

149 c model assessment of insulin resistance and glycosylated hemoglobin were measured from a fasting blo

150 Samples for plasma glucose and for glycosylated hemoglobin were obtained at 24-28 weeks' ge

151 Glycosylated hemoglobin, which was 10.4% pretreatment, d